ClinicalTrials.gg
RecruitingNCT07052266FOCUSUpdated Nov 18, 2026

Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

An interventional study of MyRisk Hereditary Cancer Test in Hereditary Cancer Syndromes, sponsored by Weill Medical College of Cornell University. Recruiting at 5 sites in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.

Planned enrollment
10th of 18
550 · median 588
Started
2025
with 3 others
No phase
17 of 33
11 open now
Primary completion
2027-06
later than 4 of 18 live
Registered
29th of 33
by date
Lead sponsor
3 of 33
Weill Medical College of Cornell University

Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 10th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 17 with no phase, reaches primary completion later than 4 of the 18 other live ones, and was the 29th registered.

Neoplastic Syndromes, Hereditary

47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.

Browse Neoplastic Syndromes, Hereditary studies →

Open to participants now

19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evaluate the acceptability of BRCA1/2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.

Read the detailed description

The purpose of this study is to prospectively offer obstetric patients combined hereditary cancer screening (HCS) and obstetric carrier screening (OCS) to see if patients decide they want HCS in addition to their OCS. Preconception and pregnancy represent a unique window of opportunity for women to engage and interact with the healthcare system. With the proposed trial, the investigators aim to change the paradigm of obstetrical-related genetic testing to include potentially life-saving HCS.

Approximately 25% of the general population in the U.S. meets established criteria to recommend genetic counseling and testing for hereditary cancer syndromes, but less than 1% of individuals undergo genetic testing. Furthermore, racial, ethnic, and linguistic minorities experience even greater under-recognition of familial cancer syndromes.This results in a critical missed opportunity for preventing cancer-associated morbidity and mortality. Obstetric care is a potential window of opportunity for addressing this issue, as pregnancy offers a unique opportunity for individuals to interact with the healthcare system. Importantly, patients are already being introduced to the topics of genetic testing and counseling, as the American College of Obstetricians and Gynecologists (ACOG) recommends that all pregnant women receive information regarding carrier screening. The uptake of OCS to evaluate hundreds of disorders is increasing rapidly, with a recent meta-analysis finding that 39% of patients undergo such testing. Currently, however, most cancer-associated mutations are not included in OCS assays. Screening reproductive-age women presents a unique opportunity to perform testing at a time when precancer screening, chemoprevention, and/or risk-reducing surgery is most beneficial.

Limited prior literature suggests that 50-75% of patients would accept combined HCS/OCS if offered. The investigators offered hereditary cancer risk assessment to 100 obstetrical patients in a diverse, Medicaid-predominant Weill Cornell Medicine clinic and found that 66% of patients were interested in cancer risk assessment during pregnancy. Furthermore, the investigators recently published a cost-effectiveness analysis suggesting that incorporation of BRCA1 genetic testing to all patients, regardless of family history at the time of OCS, is a cost-effective management strategy that can result in the prevention of breast and ovarian cancer cases and cancer deaths. Additionally, patient interviews suggest that more than 50% of patients mistakenly believed their OCS included cancer genes. This misconception poses a significant risk, as these patients assume that they had comprehensive testing and no hereditary cancer risk. Therefore, additional testing was believed to be unnecessary. Finally, prior theoretical patient surveys suggest high levels of interest in this combination testing among ethnically diverse populations. However, there has yet to be a prospective study offering patients the combined HCS/OCS, and all reported interests remain theoretical.

03

Conditions studied

  • Hereditary Cancer Syndromes

Keywords

  • Genetic Testing
  • Carrier Screening
  • Prenatal Screening
  • Reproductive Genetic Testing
  • Feasibility Study
  • Universal Screening
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years - 55 years
  • Pregnant patients receiving obstetrical-related care or receiving preconception/fertility care at a WCM-affiliated enrollment site.
  • Patients who have elected to undergo OCS with the WCM-affiliated obstetrics provider
  • Patients with prior OCS but planned to repeat OCS are eligible
  • Patients can speak and read in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously completed a multigene hereditary cancer syndrome panel
  • Patients who have a hematologic cancer or hematologic pre-cancer
  • Patients who have a history of an bone marrow transplant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Collection of HCS and OCS for patients receiving obstetrical-related care

    The first arm is for an obstetrical/prenatal (standard arm) setting

    Genetic: MyRisk Hereditary Cancer Test

  • Experimental
    Collection of HCS and OCS for patients receiving preconception/fertility care

    This second arm is at reproductive endocrinology and infertility clinics (preconception arm)

    Genetic: MyRisk Hereditary Cancer Test

Interventions

  • GeneticMyRisk Hereditary Cancer Test

    Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Complete Both HCS and OCS

    Percentage of enrolled participants who successfully complete both HCS and OCS during the study period. Completion is defined as having documented results for both screenings

    Time frame: Approximately within the end of recruitment expected at 2 years

Secondary outcomes

  1. Percentage of Participants Completing Both HCS and OCS, Stratified by Demographic and Clinical Characteristics

    The percentage of participants who complete both HCS and OCS, stratified by patient race, ethnicity, language, gestational age, insurance provider, personal cancer history, and family cancer history. Completion is defined as having documented results for both screenings.

    Time frame: Approximately at the end of recruitment, expected at 2 years.

  2. Percentage of High-Risk Participants Utilizing Guideline-Based Cancer Mitigation Strategies

    Among participants who complete both HCS and OCS and are identified as being at elevated cancer risk, this measure captures the percentage who undergo one or more guideline-based cancer mitigation strategies, such as mammogram, breast MRI, or colonoscopy.

    Time frame: From completion of screening up to 18 months post-screening

  3. Participant Experience with Combined HCS and OCS measured by the NCCN Distress Thermometer

    Participant experience with combined HCS and OCS will be assessed using a National Comprehensive Cancer Network (NCCN) validated scale called the Distress Thermometer. It is a single-item scale ranging from 0 (no distress) to 10 (extreme distress). A lower score indicates less distress, while a higher score signifies greater distress.

    Time frame: The questionnaire is received right after genetic counseling regarding HCS has been received.

  4. Participant Experience with Combined HCS and OCS measured by Satisfaction with Genetic Counseling Scale

    Participant experience with combined HCS and OCS will be assessed using a validated Satisfaction with Genetic Counseling Scale. It is a 10-item Likert scale (1-5) assessing satisfaction with counseling, including both positively and negatively worded items (reverse-scored). Total scores range from 10 to 50, with higher scores indicating greater satisfaction.

    Time frame: The questionnaire is received right after genetic counseling regarding HCS has been received.

  5. Participant Experience with Combined HCS and OCS measured by Satisfaction with Decision Scale

    Participant experience with combined HCS and OCS will be assessed using a validated Satisfaction with Decision Scale. It is a 6-item Likert scale (1-5) measuring satisfaction with the decision to undergo genetic testing. Scores range from 6 to 30; higher scores indicate greater satisfaction.

    Time frame: The questionnaire is received right after genetic counseling regarding HCS has been received.

  6. Participant Experience with Combined HCS and OCS - Qualitative Interview

    A subset of participants will complete a semi-structured interview to explore their experiences with being offered hereditary cancer screening alongside obstetrical carrier screening. Interview topics include perceptions of how screening information was presented, reasons for accepting or declining genetic testing, challenges faced in the decision-making and testing process, and suggestions for improving the patient experience. Interviews will be audio-recorded with consent, transcribed, and analyzed using thematic analysis.

    Time frame: From completion of screening up to 18 months post-screening

  7. Provider Experience with Combined HCS and OCS - Qualitative Interview

    This qualitative outcome measure assesses providers' experiences with the implementation and delivery of combined HCS and OCS through a semi-structured interview. Themes explored include prior experiences discussing genetic testing during obstetrical visits, perceptions of screening timing and appropriateness during pregnancy, challenges encountered, and suggestions for improving the screening process. Interviews will be audio-recorded, transcribed, and thematically analyzed.

    Time frame: From completion of screening up to 18 months post-screening

07

Study locations

4 of 5 sites recruiting
  • Reproductive Medicine
    Brooklyn, New York 11201, United States
    Recruiting
  • NewYork-Presbyterian Weill Cornell Medicine
    Brooklyn, New York 11215, United States
    Not yet recruiting
  • Reproductive Medicine
    New York, New York 10021, United States
    Recruiting
  • Weill Cornell Medicine
    New York, New York 10065, United States
    Recruiting
  • NewYork-Presbyterian Weill Cornell Medicine Queens
    Queens, New York 11355, United States
    Recruiting
08

References and documents

Publications

  • Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health. 2015 Sep;42(5):533-44. doi: 10.1007/s10488-013-0528-y. PubMed 24193818 ↗
  • Kaphingst KA, Bather JR, Daly BM, Chavez-Yenter D, Vega A, Kohlmann WK. Interest in Cancer Predisposition Testing and Carrier Screening Offered as Part of Routine Healthcare Among an Ethnically Diverse Sample of Young Women. Front Genet. 2022 Apr 14;13:866062. doi: 10.3389/fgene.2022.866062. eCollection 2022. PubMed 35495140 ↗
  • Dioun SM, Perez LR, Prabhu M, Brewer JT, Ahsan MD, Hou JY, Sharaf RN, Wright JD, Frey MK. Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention. Am J Obstet Gynecol. 2024 Sep;231(3):330.e1-330.e14. doi: 10.1016/j.ajog.2024.04.014. Epub 2024 Apr 14. PubMed 38621481 ↗
  • Grant BJ, Chandler I, Son M, Dioun S, Mcdougale A, Sharaf RN, Frey MK. Pregnancy: an underutilized window of opportunity for genetic cancer risk assessment. Am J Obstet Gynecol. 2025 Jan;232(1):e11-e13. doi: 10.1016/j.ajog.2024.09.100. Epub 2024 Sep 19. No abstract available. PubMed 39306315 ↗
  • Zhong L, Bather JR, Daly BM, Kohlmann WK, Goodman MS, Rothwell E, Kaphingst KA. Investigation of interest in and timing preference for cancer predisposition testing and expanded carrier screening among women of reproductive age. PEC Innov. 2023 Jan 24;2:100128. doi: 10.1016/j.pecinn.2023.100128. eCollection 2023 Dec. PubMed 37214524 ↗
  • Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC, Schneider A, Stoll K, Wapner R, Watson MS. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol. 2015 Mar;125(3):653-662. doi: 10.1097/AOG.0000000000000666. PubMed 25730230 ↗
  • Goldberg JD, Pierson S, Johansen Taber K. Expanded carrier screening: What conditions should we screen for? Prenat Diagn. 2023 Apr;43(4):496-505. doi: 10.1002/pd.6306. Epub 2023 Jan 18. PubMed 36624552 ↗
  • Committee Opinion No. 691: Carrier Screening for Genetic Conditions. Obstet Gynecol. 2017 Mar;129(3):e41-e55. doi: 10.1097/AOG.0000000000001952. PubMed 28225426 ↗
  • ACOG Committee Opinion No. 752: Prenatal and Perinatal Human Immunodeficiency Virus Testing. Obstet Gynecol. 2018 Sep;132(3):e138-e142. doi: 10.1097/AOG.0000000000002825. PubMed 30134428 ↗
  • Pazol K, Robbins CL, Black LI, Ahrens KA, Daniels K, Chandra A, Vahratian A, Gavin LE. Receipt of Selected Preventive Health Services for Women and Men of Reproductive Age - United States, 2011-2013. MMWR Surveill Summ. 2017 Oct 27;66(20):1-31. doi: 10.15585/mmwr.ss6620a1. PubMed 29073129 ↗
  • Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, Bergeron H, Chapman-Davis E, Cantillo E, Holcomb K, Blank SV, Liu Y, Thomas C, Christos PJ, Wright DN, Lipkin S, Offit K, Frey MK. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecol Oncol. 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19. PubMed 34023131 ↗
  • Guzauskas GF, Garbett S, Zhou Z, Schildcrout JS, Graves JA, Williams MS, Hao J, Jones LK, Spencer SJ, Jiang S, Veenstra DL, Peterson JF. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Ann Intern Med. 2023 May;176(5):585-595. doi: 10.7326/M22-0846. Epub 2023 May 9. PubMed 37155986 ↗
  • Offit K. The future of clinical cancer genomics. Semin Oncol. 2016 Oct;43(5):615-622. doi: 10.1053/j.seminoncol.2016.10.002. Epub 2016 Oct 18. PubMed 27899195 ↗
  • Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5. PubMed 25192939 ↗
  • Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. PubMed 28873162 ↗
  • Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol. 2017 Dec 1;35(34):3800-3806. doi: 10.1200/JCO.2017.73.6314. Epub 2017 Aug 18. PubMed 28820644 ↗
  • US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. PubMed 31429903 ↗
  • de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, Nagengast FM, Nelis FG, Rookus MA, Vasen HF. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006 Mar;130(3):665-71. doi: 10.1053/j.gastro.2005.11.032. PubMed 16530507 ↗
  • Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237. PubMed 20810374 ↗
  • Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S. Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. J Clin Oncol. 2020 May 1;38(13):1398-1408. doi: 10.1200/JCO.19.02010. Epub 2020 Jan 10. PubMed 31922925 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07052266
Collaborators
Myriad Genetics, Inc.
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Sep 2, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Steve Lopez, BA
Contact
stl4013@med.cornell.edu
9143127488
Ravi Sharaf, MD, MS
Contact
ras9030@med.cornell.edu
212-746-4014
Melissa Frey, MD, MS
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion